Edition:
United States

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.75USD
23 Apr 2018
Change (% chg)

$0.15 (+3.26%)
Prev Close
$4.60
Open
$4.50
Day's High
$4.75
Day's Low
$4.50
Volume
19,830
Avg. Vol
7,794
52-wk High
$8.55
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Kamada Ltd Q4 Earnings Per Share $0.16
Wednesday, 7 Feb 2018 07:00am EST 

Feb 7 (Reuters) - Kamada Ltd ::KAMADA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017.Q4 EARNINGS PER SHARE $0.16.Q4 REVENUE ROSE 47 PERCENT TO $35.7 MILLION.SEES FY 2018 REVENUE $116 MILLION TO $120 MILLION.SEES FY 2018 REVENUE UP 13 TO 17 PERCENT.SAYS ‍REAFFIRMING GUIDANCE OF $116 TO $120 MILLION IN TOTAL REVENUES FOR 2018​.  Full Article

Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Kamada Ltd ::KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM.KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS.KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018.KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019.  Full Article

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 07:00am EST 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

Kamada announces CFO transition
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Kamada Ltd :Kamada announces CFO transition.Kamada Ltd - Gil Efron, (deputy CEO) & Chief Financial Officer (CFO), recently informed company of his plan to leave at end of year.Kamada Ltd - Chaime Orlev will succeed as CFO, effective January 1, 2018.  Full Article

Kedrion, Kamada win FDA approval for rabies treatment
Friday, 25 Aug 2017 07:00am EDT 

Aug 25 (Reuters) - Kamada Ltd :Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection.Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection.Kamada ltd - ‍kedrab will launch in u.s. In early 2018​.Kamada ltd - ‍revenues from the product are not included in guidance of reaching $100 million in total revenue in 2017​.  Full Article

Kamada Q2 earnings per share $0.13
Tuesday, 1 Aug 2017 06:30am EDT 

Aug 1 (Reuters) - Kamada Ltd ::Kamada reports financial results for second quarter and first six months of 2017.Q2 earnings per share $0.13.Sees FY 2017 revenue $100 million.Q2 revenue rose 71 percent to $33 million.Qtrly total revenues were $32.5 million, a 71% increase from $19.1 million reported in q2 of 2016.Kamada Ltd sees FY proprietary products revenues between $76 and $78 million and distributed products revenues between $22 and $24 million.Kamada Ltd - as of June 30, 2017, co had cash, cash equivalents and short term investments of $26.9 million.Qtrly earnings per share $0.13.Qtrly adjusted net income was $5.1 million.  Full Article

Kamada announces pricing of public offering of ordinary shares
Friday, 28 Jul 2017 09:27am EDT 

July 28 (Reuters) - Kamada Ltd :Kamada Ltd - pricing of 3.33 million of its ordinary shares at a price of $4.50 per share.  Full Article

Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin
Thursday, 22 Jun 2017 07:00am EDT 

June 22 (Reuters) - Kamada Ltd :Kamada announces withdrawal of European Marketing Authorization application for inhaled ALPHA-1 antitrypsin for treatment of ALPHA-1 antitrypsin deficiency disease.Kamada Ltd -following discussions with EMA, Kamada concluded that EMA does not view data submitted to date as sufficient for approval of MAA.Says Kamada intends to utilize data to be obtained from pivotal study to resubmit MAA to EMA.Kamada - is currently in advanced discussions with U.S. FDA to secure approval of IND this year to conduct U.S. phase 3 pivotal study of inhaled AAT for treatment of AATD that would begin in 2018.  Full Article

Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Kamada Ltd :Kamada receives additional milestone payment under glassia® exclusive supply and distribution agreement with shire.Kamada receives additional milestone payment under glassia® exclusive supply and distribution agreement with shire.Kamada Ltd - milestone payment was triggered by shire achieving a sales milestone for glassia in u.s.Kamada Ltd - recently shipped all of proprietary products-related revenues, totaling approximately $11.5 million, which were previously delayed from q1.Kamada Ltd - as detailed by kamada in its q1 financial results, revenues from shipment were shifted from q1 and will be recorded in q2.Kamada Ltd - announced receipt of an undisclosed additional milestone payment under supply and distribution agreement with shire for glassia.  Full Article

BRIEF-Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet For Its Product PPP001 In Israel

* TETRA BIO-PHARMA SIGNS LANDMARK COMMERCIALIZATION TERM SHEET FOR ITS LEAD PHARMACEUTICAL PRODUCT, PPP001, IN ISRAEL

No consensus analysis data available.